CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle

Tian,Yuan; Huang,Changjun; Zhang,Hai; Ni,Qingfeng; Han,Sheng; Wang,Dong; Han,Zeguang; Li,Xiangcheng

doi:10.3892/ijo.2013.2142

CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle

Authors:
- Yuan Tian
- Changjun Huang
- Hai Zhang
- Qingfeng Ni
- Sheng Han
- Dong Wang
- Zeguang Han
- Xiangcheng Li
View Affiliations

Affiliations: Liver Transplantation Center, First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Liver Transplantation, Ministry of Public Health, Nanjing, P.R. China, Shanghai-MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, P.R. China
Published online on: October 17, 2013 https://doi.org/10.3892/ijo.2013.2142
Pages: 2082-2090

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cell division cycle-associated 7-like protein (CDCA7L) is a recently-identified target gene of c-Myc which can also interact with c-Myc. It is known to be upregulated in many tumors, however, its role in tumor progression remains unclear. We investigated the role of CDCA7L expression in hepatocellular carcinoma (HCC). We confirmed that CDCA7L is strongly upregulated in human HCC, and demonstrated that ectopic overexpression of CDCA7L promotes HCC cell proliferation and colony formation. Conversely, knockdown of CDCA7L inhibits these malignant phenotypes. In an in vivo model, subcutaneous transplantation of the tumor in nude mice showed that overexpression of CDCA7L can accelerate the tumor growth rate. Mechanistic analyses indicated that CDCA7L was able to activate the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway and regulate the cell cycle, thus promoting HCC progression. Collectively, these findings show that CDCA7L plays a role in promoting the development of HCC and may constitute a potential therapeutic target in HCC.

View Figures

View References

1.	Kan Z, Zheng H, Liu X, et al: Whole genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23:1422–1433. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Wei Y, Doria C and Liu Y: Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol. 7:87–102. 2013. View Article : Google Scholar : PubMed/NCBI
3.	Dai L, Lei N, Liu M and Zhang JY: Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Exp Hematol Oncol. 2:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
4.	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (Review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
5.	Wang X, Chen J, Li F, et al: MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun. 428:525–531. 2012.PubMed/NCBI
6.	Hakami A, Ali A and Hakami A: Effects of hepatitis B virus mutations on its replication and liver disease severity. Open Virol J. 7:12–18. 2013. View Article : Google Scholar : PubMed/NCBI
7.	Jeong SW, Jang JY and Chung RT: Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol. 18:347–356. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Zhao Y, Jian W, Gao W, et al: RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell. Cancer Cell Int. 13:23–28. 2013. View Article : Google Scholar : PubMed/NCBI
9.	Oster SK, Ho CS, Soucie EL and Penn LZ: The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 84:81–154. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Pelengaris S and Khan M: The many faces of c-MYC. Arch Biochem Biophys. 416:129–136. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Facchini LM and Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12:633–651. 1998.PubMed/NCBI
12.	Schmidt EV: The role of c-myc in cellular growth control. Oncogene. 18:2988–2996. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Boyd KE and Farnham PJ: Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol. 17:2529–2537. 1997.PubMed/NCBI
14.	Bello-Fernandez C, Packham G and Cleveland JL: The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA. 90:7804–7808. 1993. View Article : Google Scholar : PubMed/NCBI
15.	Wu S, Pena A, Korcz A, Soprano DR and Soprano KJ: Over expression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene. 12:621–629. 1996.PubMed/NCBI
16.	Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R and Dang CV: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 94:6658–6663. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Hubank M and Schatz DG: Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 22:5640–5648. 1994. View Article : Google Scholar : PubMed/NCBI
18.	Perez-Roger I, Solomon DL, Sewing A and Land H: Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 14:2373–2381. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Galaktionov K, Chen X and Beach D: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 382:511–517. 1996. View Article : Google Scholar : PubMed/NCBI
20.	Ou XM, Chen K and Shih JC: Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA. 103:10923–10928. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Huang A, Ho CS, Ponzielli R, et al: Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res. 65:5607–5619. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Chen K, Ou XM, Chen G, et al: R1, a novel repressor of the human monoamine oxidase A. J Biol Chem. 280:11552–11559. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Johnson S, Stockmeier CA, Meyer JH, et al: The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology. 36:2139–2148. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Dai CX, Gao Q, Qiu SJ, et al: Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer. 9:418–428. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Dituri F, Mazzocca A, Peidro FJ, et al: Differential inhibition of the TGF-b signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-b receptor type II. PLoS One. 8:67109–67123. 2013. View Article : Google Scholar : PubMed/NCBI
26.	Lin C-P, Liu C-R, Lee C-N, et al: Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2:16–20. 2010.PubMed/NCBI
27.	Prescott JE, Osthus RC, Lee LA, et al: A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem. 276:48276–48284. 2001.PubMed/NCBI
28.	Goto Y, Hayashi R, Muramatsu T, et al: JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity. Biochim Biophys Acta. 1759:60–68. 2006. View Article : Google Scholar
29.	Osthus RC, Karim B, Prescott JE, et al: The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. 65:5620–5627. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Gill RM, Gabor TV, Couzens AL, et al: The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Mol Cell Biol. 33:498–513. 2012. View Article : Google Scholar : PubMed/NCBI
31.	Wang H, Wu K, Sun Y, et al: STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep. 45:629–634. 2012. View Article : Google Scholar : PubMed/NCBI
32.	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
33.	Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE and Dzau VJ: Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol. 24:845–850. 2004. View Article : Google Scholar : PubMed/NCBI
34.	Braun-Dullaeus RC, Man MJ and Dzau VJ: Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:82–89. 1998. View Article : Google Scholar : PubMed/NCBI
35.	Tarn WY and Lai MC: Translational control of cyclins. Cell Div. 6:5–13. 2011. View Article : Google Scholar
36.	Ajchenbaum F, Ando K, DeCaprio JA and Griffin JD: Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem. 268:4113–4119. 1993.PubMed/NCBI
37.	Liu Y, Li W, Ye C, et al: Gambogic Acid induces G0/G1 cell cycle arrest and cell migration inhibition via suppressing PDGF receptor β tyrosine phosphorylation and Rac1 activity in Rat aortic smooth muscle cells. J Atheroscler Thromb. 17:901–913. 2010.PubMed/NCBI